Results 71 to 80 of about 6,619 (182)

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients

open access: yesCase Reports in Nephrology and Dialysis, 2020
Tolvaptan, a vasopressin V2 receptor antagonist, was initially approved in Japan for treatment of autosomal dominant polycystic kidney disease (ADPKD).
Shinya Nakatani   +8 more
doaj   +1 more source

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

open access: yesKidney International Reports, 2017
In the randomized placebo-controlled Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 trial, tolvaptan slowed kidney growth and renal function decline in subjects with autosomal ...
Olivier Devuyst   +4 more
doaj   +1 more source

Salt Intake and Kidney Outcomes in Older Adults With Chronic Kidney Disease: A Stage‐Specific Cohort Study

open access: yesNephrology, Volume 31, Issue 9, September 2026.
ABSTRACT Aim In patients with chronic kidney disease (CKD), salt restriction has been shown to lower blood pressure and proteinuria and to provide kidney protective effects. However, the benefit of salt restriction in older adults with CKD remains unclear, particularly in advanced stages.
Hiroaki Miyauchi   +5 more
wiley   +1 more source

DataSheet1_Preclinical evaluation of tolvaptan and salsalate combination therapy in a Pkd1-mouse model.PDF

open access: yes, 2023
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disorder and an important cause of end stage renal disease (ESRD).
Anish A. Kanhai (14456670)   +5 more
core   +1 more source

Development of plant‐derived biomimetic nanoparticles as a novel targeted drug delivery platform

open access: yesClinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Plant‐derived biomimetic nanoparticles (PD‐BNPs) represent a sustainable and biocompatible nanoplatform for targeted drug delivery. This review highlights their therapeutic potential, engineering strategies, and translational challenges toward precision nanomedicine applications. Abstract Plant‐derived biomimetic nanoparticles (PD‐BNPs) have emerged as
Jihad Hasan   +3 more
wiley   +1 more source

Toward the harmonization of bioequivalence guidelines in Europe: Commentary on the state of the art and future priorities under ICH M13A for immediate‐release oral forms

open access: yes
British Journal of Clinical Pharmacology, EarlyView.
Domenico Nocera   +7 more
wiley   +1 more source

Sinusoidal Obstruction Syndrome With Inotuzumab Ozogamicin Combined With Ponatinib for Philadelphia‐Chromosome‐Positive Lymphoblastic Malignancies

open access: yeseJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Sinusoidal obstruction syndrome, also known as veno‐occlusive disease (SOS/VOD), can occur after exposure to inotuzumab ozogamicin (InO), a calicheamicin‐based antibody‐drug conjugate. Case Presentation We experienced two cases of SOS/VOD after treatment with InO combined with intermittent administration of ponatinib without ...
Emi Yokoyama   +10 more
wiley   +1 more source

Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes [PDF]

open access: yes, 2016
Tolvaptan is a selective V2-receptor antagonist primarily metabolized by CYP 3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug ...
Brouwer, Kenneth R.   +7 more
core   +1 more source

Tolvaptan [PDF]

open access: yesBritish Journal of Clinical Pharmacology, 2011
Eline A, Dubois   +2 more
openaire   +3 more sources

Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial

open access: yesBMC Gastroenterology, 2020
Background To determine the safety and efficacy of different doses of tolvaptan for treating Chinese cirrhotic patients with or without hyponatraemia who still had ascites after routine therapy with diuretics.
Jieting Tang   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy